Is SUNSHINE BIOPHARMA INC (OTCMKTS:SBFM)’s Fuel Running Low? Reports Show More Sellers

March 11, 2018 - By Ellis Scott

The stock of SUNSHINE BIOPHARMA INC (OTCMKTS:SBFM) registered an increase of 19.68% in short interest. SBFM’s total short interest was 29,800 shares in March as published by FINRA. Its up 19.68% from 24,900 shares, reported previously. The short interest to SUNSHINE BIOPHARMA INC’s float is 0.01%.

The stock increased 7.38% or $0.00062 during the last trading session, reaching $0.00902. About 543,628 shares traded. Sunshine Biopharma, Inc. (OTCMKTS:SBFM) has 0.00% since March 11, 2017 and is . It has underperformed by 16.70% the S&P500.

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on researching, developing, and commercializing drugs for the treatment of various forms of cancer. The company has market cap of $8.47 million. The firm intends to conduct Phase I clinical trials with McGill University's Jewish General Hospital in Montreal, Canada for the company's lead compound Adva-27a, which is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer, such as leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer, and other forms of cancer. It currently has negative earnings.

More recent Sunshine Biopharma, Inc. (OTCMKTS:SBFM) news were published by: which released: “Sunshine Biopharma Signs Licensing Agreement for Anastrozole, the Company’s …” on May 11, 2016. Also published the news titled: “Form 8-K Sunshine Biopharma, Inc For: Jan 01” on January 04, 2018.‘s news article titled: “Sunshine Biopharma Launches Sunshine Biopharma Canada Inc., a Wholly Owned …” with publication date: July 29, 2014 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.